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Griselimycin (GM), a natural product isolated a half century ago, is having a bit of a renaissance. After being
known for more than 50 years, it is now being pursued as a treatment for tuberculosis. With the new mech-
anism of action, excellent in vitro and in vivo activity against sensitive and drug-resistant Mycobacterium
tuberculosis, and the improved pharmacokinetic properties, the cyclohexyl derivative of GM demonstrates
a high translational potential.
Tuberculosis (Tb), caused by Mycobacte-
rium tuberculosis (Mtb), is one of the major
global infectious diseases. Even though
9 million cases were reported in 2013,
with 1.5 million deaths per year (World
Health Organization, 2014), the treatment
of the infection is managed by old drugs
discovered in the 1950s and 1960s. The
regimenstartswitha fourdrugcombination
consisting of isoniazid, rifampicin, etham-
butol, and pyrazinamide for 2 months, fol-
lowed by the combination of isoniazid and
rifampicin for another4months. In2012,af-
ter some 40 years of almost no progress in
anti-Tb drug discovery, two new
drugs were approved: bedaquiline,
which targets the ATP synthase, and
delamanid, a nitroimidazole that re-
leases toxic nitric oxidewhenmetab-
olized. Bothbedaquiline anddelama-
nid are active against multidrug-
resistant (MDR) tuberculosis and
thus are able to tackle the huge resis-
tance problem. Some additional
compounds are in the pipeline in
different stages of clinical trials.
Along with the urgent need to
solve the problems with MDR and
extremely drug-resistant (XDR)
strains, there is also a real necessity to
find new antibiotics, which will allow a far
shorter treatment with a lower number of
drugs. Moreover, the new anti-infectives
must work well with other drugs because
Tb is often associated with HIV, especially
in sub-Saharan Africa (where there were
approximately 350,000 death in 2013),
and diabetes. Finally, because Tb occurs
mostly in low-income countries, the new
drugs should be cheap. The bottom line
is that new, effective, safe, and cheap
anti-Tb drugs with different mechanism
of action must be developed to address
the significant challenge that Tb poses
for public health.
Most molecules that are currently being
explored as anti-Tb treatments options
fall into the small molecule category,
although there is an increasing interest in
exploring natural products in this context.
Cyclic peptide griselimycin (GM, Figure 1)
was isolated in the 1960s from Strepto-
myces and its antibacterial and antimyco-
bacterial activity was evaluated in the
early 1970s (Terlain and Thomas, 1971a,
1971b). The early work established that
GM has unfavorable pharmacokinetic
properties, and, given that rifam-
picin was approved at that time,
the development of GM as an anti-
Tb drug was terminated. Recently,
Rolf Mu¨ller and colleagues decided
to revisit GM, given its high activity
(Kling et al., 2015). First, they
increased the metabolic stability of
GM by alkylation of the proline resi-
due in position 8. A cyclohexyl GM
(CGM) derivative, obtained via a
newly developed total synthesis,
was metabolically stable, and the
increased lipophilicity enhanced
the penetration of the thick
Figure 1. Structural Formula of Griselimycin
Alkylation of the proline ring in position 8 reveals an improve-
ment of the pharmacokinetics.
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mycobacterial cell wall, resulting in a min-
imal inhibition concentration of 0.06 mg/
ml. The activity against resistant Mtb
was similar, indicating the lack of cross-
resistances with anti-Tb drugs in use.
This also pointed to a different mecha-
nism of action of the GM derivatives
from the other mycobactericidal drugs.
The investigation of the self-resistance
to GM in Streptomyces as well as GM
resistance in mycobacteria revealed the
amplification the dnaN gene. This gene
encodes DnaN, the DNA polymerase
sliding clamp that anchors the DNA to
DNA polymerase and thus confers high
processivity to the replicative enzyme, re-
sulting in the acceleration of the DNA
replication and repair in prokaryotes.
Kling et al. (2015) demonstrate that
DnaN is the molecular target of GM by
performing surface plasmon resonance
(SPR) analyses of GM, the methyl and cy-
clohexyl derivatives using the DnaN from
different bacteria as well as human
DnaN (i.e., PCNA). Whereas the dissocia-
tion constants could be measured for the
bacterial DnaN with all GM derivatives, no
binding to the human PCNA was de-
tected, pointing to a good selectivity.
The SPR results were further supported
by X-ray structures of co-crystals of GM
and CGM with DnaN. The GM derivatives
bound to a hydrophobic pocket between
domain II and III of the clamp, which was
previously characterized as the interac-
tion site between the sliding clamp and
DNA polymerase as well as other DNA-
modifying enzymes.
CGM is orally bioavailable, and mouse
experiments performed by oral adminis-
tration show that in an acute mouse
model, the bacterial growth and gross
lung lesion could be prevented applying
a dose of 50 mg/kg of CGM. In a chronic
model, the number of colony forming
units could be decreased to the same
extent as with rifampicin. These findings
of monotherapy initiated the test of com-
binations of GM with classical anti-Tb
drugs. The combination with rifampicin
and pyrazinamide gave impressive re-
sults stressing the high in vivo activity
against replicating Mtb in addition to
bactericidal activity against non-repli-
cating bacteria.
Peptidic as well as small molecule in-
hibitors of similar sliding clamps have
recently been described for some Gram-
positive and -negative bacteria (e.g.,
Georgescu et al., 2008; Kjelstrup et al.,
2013; Wolff et al., 2014; Yin et al., 2014,
2015) emphasizing the significance of
this target. However, none of these inhib-
itors is as potent as CGM and none is
currently in clinical trials. Because there
is no pre-existing resistance due to the
new anti-Tb mechanism of action, and
the frequency of resistance seems to be
low, GM and its derivatives have the po-
tential to be moved forward to preclinical
trials.
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